The recommended dose of vomitinib is 80mg/dose taken orally once a day, but it should be used under the supervision of a doctor. Vomitinib is an epidermal growth factor receptor kinase inhibitor that is primarily used in the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer. Common adverse effects of vomitinib include rash, pruritus, diarrhea, cardiac arrhythmia, proteinuria, hepatic impairment, interstitial lung disease, vision loss, etc. It is generally contraindicated in people who are allergic to the drug, and should be used with caution in pregnant women and breastfeeding women. Vomitinib specific treatment should be carried out under the guidance of a doctor, if there are adverse reactions, should consult a doctor in time.